The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback